Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01536249 · ClinicalTrials.gov registry record · Phase 1

Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)

A Phase 1 study, sponsored by Knopp Biosciences.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target

NCT01536249 is a Phase 1 study that has completed, run by Knopp Biosciences. The registered enrollment target is 14 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01536249, a Phase 1 study, has completed, sponsored by Knopp Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target

Study Summary

This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine. Additionally, this study will explore the influence of genetic variation on the PK of dexpramipexole when given with or without cimetidine.

Interventions

  • DRUG Dexpramipexole
  • DRUG Cimetidine plus Dexpramipexole

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2012-03
Est. Completion 2012-04
Phase Phase 1

Sponsor

Knopp Biosciences

12 total trials

What the Registry Record Tells You About NCT01536249

The ClinicalTrials.gov registry entry for NCT01536249 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Dexpramipexole is the first listed.

NCT01536249 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01536249 about?

NCT01536249 is a clinical study titled "Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)". This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine. Additionally, this study will explore the influence of genetic variation on the PK of ...

What is the current status of trial NCT01536249?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2012-04.

What interventions are being tested in trial NCT01536249?

The interventions under investigation include: Dexpramipexole (DRUG), Cimetidine plus Dexpramipexole (DRUG).

Who is sponsoring clinical trial NCT01536249?

This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.